Epigenetic Modulators 2

• 7054 · PDF BET domain functions in IDH1 R132H /p53 mut /ATRX loss astrocytoma malignancy Leyi Xie, Qingzhu Gao, Jayden Zhang, Lopez-BertoniHernando, John Laterra, Yunqing Li
• 7055 · PDF Synergistic effects of HM97662 as an EZH1/2 dual inhibitor combined with DNA-damaging agents on malignant lung cancers harboring SMARCA4-deficiency Seung Hyun Jung, Jaeyul Choi, Aran Park, Seungheon Baek, Jooyun Byun, Young Gil Ahn
• 7056 · PDF Telomir-1: A novel metal ion modulator targeting aging-related disorders and cancer Itzchak Angel, Erez Aminov
• 7057 · PDF Therapeutic potential of PCNA and HDAC inhibitor combinations in cutaneous T-cell lymphoma and other cancers Caroline M. Li, Robert G. Lingeman, Long Gu, Robert J. Hickey, Linda H. Malkas
• 7058 · PDF Highly selective HDAC6 inhibitors: Are they the answer for immunomodulation? Silvia Rizzo, Edoardo Cellupica, Chiara Ripamonti, Grazia Rovelli, Barbara Vergani, Valeria Spadotto, Michela Bottani, Christian Steinkuhler, Gianluca Fossati
• 7060 · PDF Targeting KMT2C induces paralog synthetic lethality in KMT2D null DLBCL through DREAM targets regulation Hsiangyu Hu, Neeraj K. Aryal, Tim Nieuwenhuis, Daniel Barrell, Ultan McDermott, Laura B. Prickett, Ming Tang, Derek Oien, Laura Pasqualucci, Anas Younes, Lisa Drew, Omid Tavana
• 7061 7061 Mechanistic understanding of a novel CBP/p300 inhibitor in fusion-positive rhabdomyosarcoma Md Imdadul H. Khan, Matthew Chang, Yaw Asante, Maya Al-Haddad, Jordyn Kelly, Bhavatharini Udhayakumar, Carrietta Farma-Hai, Berkley Gryder
• 7062 · PDF EP102: Pharmacological inhibition of METTL3 is effective as a monotherapy and potentiates radiation therapy in pancreatic adenocarcinoma via DNA damage and stemness modulation Andrea Casazza, Nicolas Parmentier, Catherine Sorlet, Killian Oukoloff, Guillaume Dutheuil, Graeme L. Fraser
• 7063 · PDF p300 bromodomain inhibitors impair cell proliferation by inducing senescence in HPV positive head and neck squamous cell carcinoma Jessica Catarine Frutuoso do Nascimento, Wendi Quinn O'Neill, Quintin Pan
• 7064 · PDF Development of a new class of KAT6A/B inhibitors with in vivo efficacy Antonius ter Laak, Roman Hillig, Steven Ferrara, Daniel Korr, Peter Staller, Naomi Barak, Philip Lienau, Simon Herbert, Amaury Fernandez, Roland Neuhaus, Matyas Gorjanacz, Vera Puetter, Volker Badock, Wilhelm Bone, Craig Strathdee, Franziska Siegel, Christoph Schatz, Nowak-Reppel Katrin, Olaf Doehr, Stefan Gradl, Ingo Hartung, Matthew Meyerson, Lea Bouche
• 7065 · PDF Targeting MTAP-deleted/KRAS mutant cancers using RAS inhibitors in combination with AMG 193, an MTA-cooperative PRMT5 inhibitor Katherine Slemmons, Siyuan Liu, Chun Su, Raul Lazaro, Tao Osgood, Rati Verma, Brian Belmontes, Paul E. Hughes
• 7066 · PDF Comparative in vivo evaluation of RG-7388, CM-272, and SGI-1027 to determine epigenetic targeting as an effective strategy for treating high-risk neuroblastoma Umamaheswari Natarajan, Shyam S. Jaganathan, Appu Rathinavelu
• 7067 · PDF Synergistic cytotoxicity through combination of DNA methyltransferase (DNMT) inhibitors in cancer cells Angelo B. A. Laranjeira, Dat Nguyen, Michael Difilippantonio, Alice P. Chen, Sherry X. Yang, James H. Doroshow
• 7069 · PDF Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged acute myeloid leukemia Tulasigeri Totiger, Mina Tayari, Claudia Cabrera Pastrana, Florencio Munoz-Legarre, Anna Kingham, Helena Gomes Dos Santos, Felipe Beckedorff, Eduardo Bravo, Katarzyna Ciurko, Declan Foley, Efe Karaca, Daniel Bilbao, Claude-Henry Claude-Henry Volmar, Shaun P. Brothers, Ramin Shiekhattar, Justin Watts, Justin Taylor
• 7070 · PDF Butyrate modulates key oncogenic pathways in oral squamous cell carcinoma: Insights from transcriptomic profiling Oscar A. Loperena Gonzalez, Ariana S. García- López, Liah M. Román-Calderón, Gabriel Borges Vélez, Esther Peterson Peguero, Josué Pérez Santiago
• 7071 · PDF CRISPRi screening identifies epigenetic vulnerabilities and an ARID1A-PRC2 synthetic-lethal axis sensitizing cutaneous T-cell lymphoma to combined JAK/STAT and EZH2 inhibition Yan-Jin Liu, Laura Pincus, Yu-Ru Chang, Frank McCormick, Weiyun Z. Ai
• 7073 · PDF Targeted inhibition of PRC1 in acute leukemia models induces prominent cell growth and differentiation effects Sydney Musser, Yiwu Yao, Se Ra Park, Miranda Simes, Hongzhi Miao, Alyssa Winkler, Trupta Purohit, Jolanta Grembecka, Tomasz Cierpicki
• 7074 · PDF PLX-61639, a potent and orally bioavailable SMARCA2-selective monovalent direct degrader, enhances efficacy of standard of care agents in SMARCA4 mutant tumor models Greg Parker, Geoffray Leriche, Aleksandar Jamborcic, Taylor Kampert, Linette Yang, Julia Toth, Kenneth Steadman, Jay Chung, Duc Tran, Luis Lopez, Farhana Barmare, Kyohei Hayashi, Gang Liu, Jianguo Ma, Alex Campos, Meg McCarrick, Kevin Freeman-Cook, Peggy Thompson
• 7075 · PDF Preclinical characterization of FHT-171, a first-in-class degrader targeting CREB-binding protein (CBP) in CBP-dependent solid tumors Darshan Sappal, Molly M. Wilson, Laura La Bonte, Meiyun Lin, Breanna Bullock, Shawn Schiller
• 7076 · PDF Discovery of a highly potent and selective KAT6A degrader ATH-002 that demonstrates robust anti-tumor activity with a low risk of hematotoxicity in preclinical studies Hanyu Wang, Lei Jiang, Youxi Chen, Baoying Chen, Yuyao Zhang, Nianfeng Huang, Fan Yang, Feng Zhou
• 7077 · PDF ISM1745, an MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancer Yilin Yang, Zhongying Cao, Meng Zhang, Xiaoyu Ding, Hongfu Lu, Qingchuan Zhao, Xiaoxia Lin, Jiaojiao Yu, David Gennert, Suguna Rachakonda, Xiao Ding, Xin Cai, Man Zhang, Feng Ren, Alex Zhavoronkov

在会议检索中浏览本分会场